

Paul Toren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5154108/publications.pdf>

Version: 2024-02-01

51
papers

935
citations

566801

15
h-index

454577

30
g-index

53
all docs

53
docs citations

53
times ranked

1697
citing authors

#	ARTICLE	IF	CITATIONS
1	Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer. <i>Asian Journal of Andrology</i> , 2022, 24, 21.	0.8	2
2	Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype. <i>Clinical and Translational Medicine</i> , 2022, 12, e581.	1.7	9
3	Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy. <i>Clinical Nutrition ESPEN</i> , 2022, 47, 221-226.	0.5	2
4	Case " Gigantic obstructive calculi in continent urinary diversion. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.3	0
5	Sex steroid modulation of macrophages within the prostate tumor microenvironment.. <i>American Journal of Clinical and Experimental Urology</i> , 2022, 10, 98-110.	0.4	0
6	Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer. <i>European Urology Focus</i> , 2021, 7, 1044-1051.	1.6	13
7	Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival. <i>World Journal of Urology</i> , 2021, 39, 1549-1558.	1.2	9
8	Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 303.e1-303.e8.	0.8	1
9	Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer. <i>Journal of Urology</i> , 2021, 206, 1166-1176.	0.2	5
10	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 1176.	0.2	0
11	Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugs. <i>Scientific Reports</i> , 2021, 11, 19299.	1.6	6
12	Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. <i>European Urology Oncology</i> , 2020, 3, 298-305.	2.6	15
13	Images " Para-aortic lymphatic ectasia suggestive of testicular cancer retroperitoneal metastasis. <i>Canadian Urological Association Journal</i> , 2020, 15, E76-E78.	0.3	0
14	A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine. <i>Canadian Urological Association Journal</i> , 2020, 14, 319-321.	0.3	11
15	Does 5-alpha Reductase Inhibitor Use Improve The Efficacy of Intravesical Bacille Calmette-Guérin (BCG) for Non-muscle Invasive Bladder Cancer?. <i>Bladder Cancer</i> , 2020, 6, 63-69.	0.2	5
16	Extragenital Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy. <i>Journal of Urology</i> , 2020, 203, 940-948.	0.2	8
17	Assembling a network to promote translational bladder cancer research in Canada. <i>Canadian Urological Association Journal</i> , 2020, 14, E475-E481.	0.3	1
18	Switching from a GnRH agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis. <i>Canadian Urological Association Journal</i> , 2019, 14, 36-41.	0.3	5

#	ARTICLE	IF	CITATIONS
19	Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients. <i>Prostate</i> , 2019, 79, 1767-1776.	1.2	51
20	Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1122-e1128.	0.9	9
21	Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 300.e9-300.e15.	0.8	21
22	Discordance between testosterone measurement methods in castrated prostate cancer patients. <i>Endocrine Connections</i> , 2019, 8, 132-140.	0.8	6
23	PEG10 is associated with treatment-induced neuroendocrine prostate cancer. <i>Journal of Molecular Endocrinology</i> , 2019, 63, 39-49.	1.1	25
24	Images - Sclerosing mesenteritis presenting with unilateral hydro-ureteronephrosis. <i>Canadian Urological Association Journal</i> , 2019, , E306-E308.	0.3	0
25	Sex steroids in the tumor microenvironment and prostate cancer progression. <i>Endocrine-Related Cancer</i> , 2018, 25, R179-R196.	1.6	24
26	Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5 α -reductase inhibitors. <i>BJU International</i> , 2018, 121, 399-404.	1.3	10
27	Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5305-5312.	3.2	13
28	Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 363.e7-363.e11.	0.8	16
29	Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0152861.	1.1	30
30	PD32-01 PRE-CLINICAL RATIONALE FOR COMBINATION PI3K AND BRD4 INHIBITION IN ADVANCED PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
31	MP62-06 COMBINED AKT AND MEK PATHWAY BLOCKADE IN PRE-CLINICAL MODELS OF ENZALUTAMIDE-RESISTANT PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
32	Pre-clinical rationale for combination PI3K and BRD4 inhibition in advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 234-234.	0.8	0
33	Analysis of the translome in solid tumors using polyribosome profiling/RNA-Seq. <i>Journal of Biological Methods</i> , 2016, 3, e59.	1.0	1
34	Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT. <i>Journal of Clinical Oncology</i> , 2015, 33, 1151-1156.	0.8	139
35	Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. <i>European Urology</i> , 2015, 67, 986-990.	0.9	91
36	Active surveillance in patients with a PSA \geq 10 ng/mL. <i>Canadian Urological Association Journal</i> , 2014, 8, 702.	0.3	12

#	ARTICLE	IF	CITATIONS
37	Periprostatic Adipose Tissue and Prostate Cancer Progression: New Insights into the Tumor Microenvironment. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 21-26.	0.9	31
38	Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review). <i>International Journal of Oncology</i> , 2014, 45, 1793-1801.	1.4	142
39	Results of a National Population-based Study of Outcomes of Surgery for Renal Tumors Associated With Inferior Vena Cava Thrombus. <i>Urology</i> , 2013, 82, 572-578.	0.5	55
40	982 COMBINED TARGETING OF PI3K/AKT AND AR PATHWAY WITH AZD5363 AND ENZALUTAMIDE INDUCES ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF PROSTATE CANCER. <i>Journal of Urology</i> , 2013, 189, .	0.2	2
41	Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2013, 15, 342-349.	0.8	27
42	Diet, Obesity, and Cancer Progression: Are Adipocytes the Link?. <i>Lipid Insights</i> , 2013, 6, LPI.S10871.	1.0	17
43	Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study. <i>BMJ, The</i> , 2013, 346, f2109-f2109.	3.0	25
44	Rational cotargeting of Pim-1 and Akt in prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 937-939.	1.1	4
45	Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: A randomized study. <i>Canadian Urological Association Journal</i> , 2013, 7, 692.	0.3	37
46	The effect of nerve-sparing surgery on patient-reported continence post-radical prostatectomy. <i>Canadian Urological Association Journal</i> , 2013, 3, 465.	0.3	13
47	Catastrophic sepsis and hemorrhage following transrectal ultrasound guided prostate biopsies. <i>Canadian Urological Association Journal</i> , 2013, 4, 12.	0.3	15
48	Use of a novel parenchymal clamp for laparoscopic and open partial nephrectomy. <i>Canadian Urological Association Journal</i> , 2013, 4, 133.	0.3	3
49	236 EXPERIENCE WITH RECTOURETHRAL FISTULA REPAIR AND DESCRIPTION OF A NOVEL SURGICAL TECHNIQUE. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
50	Comparison of epidural and intravenous patient controlled analgesia in patients undergoing radical cystectomy. <i>Canadian Journal of Urology</i> , 2009, 16, 4716-20.	0.0	21
51	The patient presenting with genitourinary AIDS. , 2005, , 263-280.		0